Cargando…

Antioxidant Activity of Deferasirox and Its Metal Complexes in Model Systems of Oxidative Damage: Comparison with Deferiprone

Deferasirox is an orally active, lipophilic iron chelating drug used on thousands of patients worldwide for the treatment of transfusional iron overload. The essential transition metals iron and copper are the primary catalysts of reactive oxygen species and oxidative damage in biological systems. T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Timoshnikov, Viktor A., Kichigina, Lilia A., Selyutina, Olga Yu., Polyakov, Nikolay E., Kontoghiorghes, George J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8401497/ https://www.ncbi.nlm.nih.gov/pubmed/34443652 http://dx.doi.org/10.3390/molecules26165064

Ejemplares similares

Metal Complexes of Omadine (N-Hydroxypyridine-2-thione): Differences of Antioxidant and Pro-Oxidant Behavior in Light and Dark Conditions with Possible Toxicity Implications
por: Selyutina, Olga Yu., et al.
Publicado: (2023)

Mechanistic Insights of Chelator Complexes with Essential Transition Metals: Antioxidant/Pro-Oxidant Activity and Applications in Medicine
por: Timoshnikov, Viktor A., et al.
Publicado: (2022)

Redox Interactions of Vitamin C and Iron: Inhibition of the Pro-Oxidant Activity by Deferiprone
por: Timoshnikov, Viktor A., et al.
Publicado: (2020)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes
por: Kontoghiorghe, Christina N, et al.
Publicado: (2016)

Chelation of Thallium (III) in Rats Using Combined Deferasirox and Deferiprone Therapy
por: Salehi, Samie, et al.
Publicado: (2017)

Increased Free Radical Generation during the Interaction of a Quinone-Quinoline Chelator with Metal Ions and the Enhancing Effect of Light
por: Selyutina, Olga Yu., et al.
Publicado: (2023)

Trying to Solve the Puzzle of the Interaction of Ascorbic Acid and Iron: Redox, Chelation and Therapeutic Implications
por: Kontoghiorghes, George J., et al.
Publicado: (2020)

Efficacy and Safety of Combined Deferiprone and Deferasirox in Iron-Overloaded Patients: A Systematic Review
por: Salem, Ahmed, et al.
Publicado: (2023)

Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox
por: Olivieri, Nancy F., et al.
Publicado: (2019)

The History of Deferiprone (L1) and the Paradigm of the Complete Treatment of Iron Overload in Thalassaemia
por: Kontoghiorghes, George J., et al.
Publicado: (2020)

Deferiprone and Iron–Maltol: Forty Years since Their Discovery and Insights into Their Drug Design, Development, Clinical Use and Future Prospects
por: Kontoghiorghes, George J.
Publicado: (2023)

Correction: Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox
Publicado: (2019)

Deferiprone: A Forty-Year-Old Multi-Targeting Drug with Possible Activity against COVID-19 and Diseases of Similar Symptomatology
por: Kontoghiorghes, George J.
Publicado: (2022)

Combination Iron Chelation Therapy with Deferiprone and Deferasirox in Iron-Overloaded Patients with Transfusion-Dependent β-Thalassemia Major
por: Karami, Hossein, et al.
Publicado: (2017)

Comparative Efficacy and Safety of Deferoxamine, Deferiprone and Deferasirox on Severe Thalassemia: A Meta-Analysis of 16 Randomized Controlled Trials
por: Xia, Sujian, et al.
Publicado: (2013)

MRI prospective survey on cardiac and hepatic iron in transfusion-dependent thalassemia intermedia patients treated with desferrioxamine, deferiprone and deferasirox
por: Meloni, Antonella, et al.
Publicado: (2015)

Comparison of iron chelation effects of deferoxamine, deferasirox, and combination of deferoxamine and deferiprone on liver and cardiac T2* MRI in thalassemia maior
por: Ansari, Shahla, et al.
Publicado: (2017)

The Vital Role Played by Deferiprone in the Transition of Thalassaemia from a Fatal to a Chronic Disease and Challenges in Its Repurposing for Use in Non-Iron-Loaded Diseases
por: Kontoghiorghes, George J.
Publicado: (2023)

A T2* MRI prospective survey on heart iron in thalassemia major patients treated with sequential deferipron-desferrioxamine versus deferasirox
por: Pepe, Alessia, et al.
Publicado: (2011)

A T2* MRI prospective survey on heart iron in thalassemia major patients treated with deferasirox versus deferiprone and desferrioxamine in monotherapy
por: Pepe, Alessia, et al.
Publicado: (2011)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes
por: Taher, Ali T, et al.
Publicado: (2016)

P1511: EFFICACY AND SAFETY OF COMBINATION IRON CHELATION THERAPY WITH DEFERIPRONE AND DEFERASIROX IN PATIENTS WITH Β-THALASSEMIA MAJOR: A SYSTEMATIC LITERATURE REVIEW
por: Piga, A., et al.
Publicado: (2022)

Efficacy and safety of combined oral iron chelation therapy with deferasirox and deferiprone in a patient with beta-thalassemia major and persistent iron overload
por: Alavi, Samin, et al.
Publicado: (2014)

Differences between the European Union and United States of America in Drug Regulatory Affairs Affect Global Patient Safety Standards and Public Health Awareness: The Case of Deferasirox and Other Iron Chelating Drugs
por: Kontoghiorghes, George J.
Publicado: (2021)

Advances on Chelation and Chelator Metal Complexes in Medicine †
por: Kontoghiorghes, George J.
Publicado: (2020)

Photoinduced Oxidation of Lipid Membranes in the Presence of the Nonsteroidal Anti-Inflammatory Drug Ketoprofen
por: Mastova, Anna V., et al.
Publicado: (2022)

The Interaction of the Transmembrane Domain of SARS-CoV-2 E-Protein with Glycyrrhizic Acid in Lipid Bilayer
por: Kononova, Polina A., et al.
Publicado: (2023)

Kidney Tubular Damage Secondary to Deferasirox: Systematic Literature Review
por: Scoglio, Martin, et al.
Publicado: (2021)

Stereoselectivity of Interaction of Nonsteroidal Anti-Inflammatory Drug S-Ketoprofen with L/D-Tryptophan in Phospholipid Membranes
por: Mastova, Anna V., et al.
Publicado: (2022)

The Interaction of Anthracycline Based Quinone-Chelators with Model Lipid Membranes: (1)H NMR and MD Study
por: Selyutina, Olga Yu., et al.
Publicado: (2023)

Deferasirox Reduces Oxidative Stress in Patients With Transfusion Dependency
por: Saigo, Katsuyasu, et al.
Publicado: (2013)

Salmonella Typhimurium and Pseudomonas aeruginosa Respond Differently to the Fe Chelator Deferiprone and to Some Novel Deferiprone Derivatives
por: Ammendola, Serena, et al.
Publicado: (2021)

Hypersensitivity reaction with deferasirox
por: Sharma, Atul, et al.
Publicado: (2015)

Ferroptosis inhibition by deferiprone, attenuates myelin damage and promotes neuroprotection in demyelinated optic nerve
por: Rayatpour, Atefeh, et al.
Publicado: (2022)

pH-Sensitive Glycyrrhizin Based Vesicles for Nifedipine Delivery
por: Selyutina, Olga Yu., et al.
Publicado: (2021)

Prospective comparison on cardiac iron by MR in thalassemia major patients treated with combination deferipron-desferrioxamine versus deferipron and desferrioxamine in monoterapy
por: Pepe, Alessia, et al.
Publicado: (2011)

Deferiprone-induced arthropathy in thalassemia: MRI findings in a case
por: Chand, Gyan, et al.
Publicado: (2009)

The Interplay of Ascorbic Acid with Quinones-Chelators—Influence on Lipid Peroxidation: Insight into Anticancer Activity
por: Selyutina, Olga Yu., et al.
Publicado: (2022)

Deferasirox: Duodenal perforation: case report
Publicado: (2021)

Deferiprone targets aconitase: Implication for Friedreich's ataxia treatment
por: Goncalves, Sergio, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_au7ua9rg9md744ol9vm8al8fpt